Quarterly report pursuant to Section 13 or 15(d)

SHARE-BASED COMPENSATION (Tables)

v3.23.1
SHARE-BASED COMPENSATION (Tables)
 3 Months Ended
Mar. 31, 2023
Equity [Abstract]  
Schedule of summarizes share-based compensation expense
               
    Three Months Ended
March 31,		  
    2023     2022  
Research and development   $ 531     $ 966  
Sales and marketing     507       1,083  
General and administrative     894       4,474  
Cost of sales     7       41  
Total share-based compensation   $ 1,939     $ 6,564  
Schedule of common stock options
                               
    Number of
Shares		     Weighted
Average
Exercise
Price		     Weighted
Average
Remaining
Contractual
Life (Years)		     Weighted-
Average
Grant Date
Fair Value		  
Outstanding, December 31, 2022     7,812,178     $ 3.70       6.56     $ 2.23  
Forfeited     (31,523 )     2.26       -       1.46  
Expired     (14,421 )     5.40       -       2.86  
Outstanding, March 31, 2023(a)     7,766,234     $ 3.70       6.32     $ 1.98  
Exercisable, March 31, 2023(b)     4,870,164     $ 4.03       4.87     $ 2.12  

 

 
(a) There was no aggregate intrinsic value of all stock options outstanding as of March 31, 2023.
(b) There was no aggregate intrinsic value of all vested/exercisable stock options as of March 31, 2023.
Schedule of Unvested Restricted Stock Units
               
    Number of
RSUs		     Weighted
Average
Grant Date
Fair Value		  
Outstanding (nonvested), December 31, 2022     4,267,746     $ 3.58  
Released     (387,204 )     5.44  
Forfeited     (49,610 )     3.07  
Outstanding (nonvested), March 31, 2023     3,830,932     $ 3.41